Supplementary Data
Olson – Long-Term Prognosis Associated with J-Point Elevation in a Large Biracial Cohort: The
ARIC Study
Contents:
Table S1. Baseline Subject Characteristics by Sudden Cardiac Death Status
Table S2. Unadjusted and Adjusted Hazard Ratios Comparing Subjects with J-Point Elevation to
Those Without, Stratified by Lead Grouping
1
Supplementary Tables
Table S1. Baseline Subject Characteristics by Sudden Cardiac Death Status
SCD
No SCD
Mean (SD) or %
Mean (SD) or %
(n=237)
(n=14,904)
56.4 (5.7)
54.0 (5.7)
Male (%)
68.4
43.9
Female (%)
31.6
56.1
White (%)
57.8
73.5
Black (%)
42.2
26.5
Body Mass Index (kg/m2)
28.9 (5.7)
27.7 (5.4)
Heart Rate (beats/min)
68.5 (11.8)
66.7 (10.3)
Systolic Blood Pressure (mm Hg)
132.9 (22.1)
121.0 (18.7)
Diastolic Blood Pressure (mm Hg)
77.7 (13.9)
73.6 (11.2)
Current Smoker (%)
36.7
25.9
Former Smoker (%)
32.5
32.2
Never Smoker (%)
30.8
42.0
Diabetic (%)
33.5
11.4
LVH by Cornell criteria (%)
6.1
1.8
1487.5 (663.8)
1210.3 (527.1)
38.8
8.9
Subject Characteristics
Age (years)
Sex
Race
Smoking Status
Cornell Voltage (µV)
Major Abnormality on ECGa (%)
2
High-Density Lipoprotein (mg/dL)
44.8 (14.0)
51.8 (17.1)
Low-Density Lipoprotein (mg/dL)
147.9 (38.7)
137.3 (39.3)
Basic (%)
43.0
23.2
Intermediate (%)
32.9
41.1
Advanced (%)
24.1
35.7
Personal History of CHD (%)
31.2
4.1
History of Stroke (%)
7.6
1.6
Angina (%)
14.4
4.8
Intermittent Claudication (%)
2.5
0.7
Family History of Premature CHD (%)
11.2
10.2
Beta-Blockers
21.1
10.5
Calcium Channel Blockers
15.2
3.2
Antiarrhythmics
1.3
0.6
Digitalis
6.8
1.4
ACE Inhibitors
6.8
3.0
Serum potassium (mmol/L)
4.35 (0.53)
4.42 (0.48)
Serum Sodium (mmol/L)
140.6 (2.5)
141.0 (2.4)
Serum Calcium (mg/dL)
9.80 (0.47)
9.79 (0.43)
Serum Magnesium (mg/mL)
1.59 (0.18)
1.63 (0.16)
Education
Cardiac Medications (%)
a
Major ECG abnormality as defined by Minnesota Code
3
Table S2. Unadjusted and Adjusted Hazard Ratios Comparing Subjects with J-Point Elevation to
Those Without, Stratified by Lead Grouping
Sudden Cardiac Death
Fatal/Nonfatal CHD
All-Cause Mortality
HR (95%CI)
HR (95% CI)
HR (95% CI)
JPE in any lead
2.28 (1.69-3.07)
1.46 (1.28-1.65)
1.40 (1.28-1.53)
JPE in leads II,III,aVF
1.69 (0.54-5.27)
1.06 (0.63-1.79)
1.52 (1.11-2.08)
JPE in leads I,V6, aVL
2.87 (1.06-7.70)
1.23 (0.71-2.12)
1.07 (0.71-1.62)
JPE in leads V1-V5
2.20 (1.62-2.99)
1.45 (1.28-1.65)
1.40 (1.27-1.53)
1.31 (0.94-1.82)d,e
1.06 (0.92-1.21)e
1.05 (0.96-1.16)
JPE in leads II,III,aVF
1.25 (0.40-3.92)
0.90 (0.53-1.52)
1.37 (1.00-1.87)
JPE in leads I,V6, aVL
1.88 (0.69-5.09)
1.06 (0.61-1.83)
0.90 (0.60-1.36)
1.23 (0.88-1.73)d,e
1.04 (0.91-1.20)e
1.04 (0.94-1.15)
1.28 (0.90-1.82)d,e
1.06 (0.92-1.23)e
1.06 (0.96-1.18)
JPE in leads II,III,aVF
1.85 (0.59-5.83)
0.89 (0.49-1.62)
1.51 (1.07-2.12)
JPE in leads I,V6, aVL
3.00 (1.09-8.26)
1.24 (0.70-2.20)
1.00 (0.64-1.55)
JPE in leads V1-V5
1.19 (0.83-1.70)d
1.05 (0.90-1.22)e
1.05 (0.94-1.17)
1.23 (0.87-1.75)d,e
1.03 (0.89-1.19)e
1.02 (0.92-1.13)
JPE in leads II,III,aVF
1.88 (0.60-5.91)
0.94 (0.52-1.71)
1.57 (1.12-2.20)
JPE in leads I,V6, aVL
2.82 (1.02-7.79)
1.28 (0.72-2.27)
1.08 (0.69-1.68)d
JPE in leads V1-V5
1.14 (0.79-1.63)d
1.02 (0.88-1.18)e
1.00 (0.90-1.11)
Unadjusted Model
Model 1a
JPE in any lead
JPE in leads V1-V5
Model 2b
JPE in any lead
Model 3c
JPE in any lead
a
Based on Cox proportional hazards model, adjusted for age, sex, and race
4
b
Based on Cox proportional hazards model, adjusted for age, sex , race, heart rate, systolic blood
pressure, BMI, serum low-density lipoprotein, diabetes, presence of major ECG abnormality, Cornell
voltage for LVH, previous CHD, history of angina or stroke
c
Based on Cox proportional hazards model, adjusted for age, sex , race, heart rate, systolic blood
pressure, BMI, serum low-density lipoprotein, diabetes, presence of major ECG abnormality, Cornell
voltage for LVH, previous CHD, history of angina or stroke, smoking status, physical activity, and serum
potassium
d
Significant race interaction present (see Table 3 for stratified HRs)
e
Significant sex interaction present (see Table 3 for stratified HRs)
5